[3] Its main offices were located in Gaithersburg, MD, Cambridge, UK, and Mountain View, CA.

[6] MedImmune conducted successful clinical trials for a new generation of FluMist needle-free vaccine, called CAIV-T, which was approved by the U.S. Food and Drug Administration (FDA) in 2007, and is now the form offered on the market.

[6] On 19 June 2007 AstraZeneca completed the acquisition paying US$ 15.2 billion primarily for its drug development pipeline.

[5] MedImmune then won a second contract to test its nasal spray flu technology as a viable treatment for the H1N1.

[10] MedImmune had over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.